Kestra Medical Technologies, Ltd. Announces | U.S. Markets

Kestra Medical Applied sciences introduced an upsized IPO of 11.9 million shares at $17, set to trade on Nasdaq.

Quiver AI Abstract

Kestra Medical Applied sciences, Ltd., a company specializing in wearable medical units and digital healthcare, introduced the pricing of its initial public offering (IPO) of 11,882,352 common shares at $17.00 per share, with an option for underwriters to buy an extra 1,782,352 shares. The shares will start trading on the Nasdaq International Choose Market underneath the image “KMTS” on March 6, 2025, with gross proceeds from the offering anticipated to succeed in roughly $202 million, excluding any extra shares bought by underwriters. The offering is set to close on March 7, 2025, pending customary situations. BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are main the underwriting course of. This press release doesn’t represent an offer to promote or buy securities, and the required registration has been filed with the U.S. Securities and Change Fee.

Potential Positives

• Kestra Medical Applied sciences efficiently priced its upsized initial public offering at $17.00 per share, indicating robust investor curiosity and confidence within the company.
• The company is set to raise roughly $202 million in gross proceeds from the offering, offering important capital to help its growth and innovation in wearable medical units.
• The upcoming itemizing on the Nasdaq International Choose Market underneath the ticker image “KMTS” enhances the company’s visibility and credibility within the investment neighborhood.

Potential Negatives

• The upsized initial public offering may point out a need for important capital, doubtlessly raising considerations concerning the company’s financial stability and its potential to generate enough income.
• The reliance on underwriters for the offering could counsel the company doesn’t have the market traction or investor confidence to undertake the IPO with out exterior help.
• The press release doesn’t present particulars on the company’s operational efficiency or growth strategy, which may result in uncertainty amongst traders concerning the long-term viability of Kestra Medical Applied sciences.

FAQ

What’s Kestra Medical Applied sciences’ initial public offering (IPO) price?

The initial public offering price is set at $17.00 per share.

When will Kestra’s shares start trading?

Kestra’s shares are anticipated to begin trading on March 6, 2025.

How a lot are the gross proceeds from the IPO?

The gross proceeds are anticipated to be roughly $202 million, excluding sure bills.

Who’re the underwriters for Kestra’s IPO?

BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are appearing as lead bookrunners.

What ticker image will Kestra’s shares trade underneath?

Kestra’s shares will trade underneath the ticker image “KMTS” on the Nasdaq International Choose Market.

Disclaimer: That is an AI-generated abstract of a press release distributed by GlobeNewswire. The model used to summarize this release could make errors. See the total release right here.

Full Launch

KIRKLAND, Wash., March 05, 2025 (GLOBE NEWSWIRE) — Kestra Medical Applied sciences, Ltd. (“Kestra”), a wearable medical system and digital healthcare company, right now introduced the pricing of its upsized initial public offering of 11,882,352 common shares at a public offering price of $17.00 per share.

As well as, the underwriters can have a 30-day over-allotment option to buy up to 1,782,352 extra common shares from Kestra on the initial public offering price, much less underwriting reductions and commissions. The common shares are anticipated to start trading on the Nasdaq International Choose Market on March 6, 2025, underneath the ticker image “KMTS.” The gross proceeds from the offering, earlier than deducting underwriting reductions and commissions and different offering bills payable by Kestra, are anticipated to be roughly $202 million, excluding any train of the underwriters’ option to buy extra common shares. The closing of the offering is predicted to happen on March 7, 2025, subject to the satisfaction of customary closing situations.

BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler are appearing as lead bookrunners for the proposed offering. Wells Fargo Securities and Stifel are appearing as bookrunners and Wolfe | Nomura Alliance is appearing as co-manager for the proposed offering.

The proposed offering is being made solely by means of a prospectus. Copies of the ultimate prospectus could also be obtained, when out there, from BofA Securities, Consideration: Prospectus Division, NC1-022-02-25, 201 North Tryon Road, Charlotte, NC 28255-0001, or by electronic mail at [email protected]; from Goldman Sachs & Co. LLC, Consideration: Prospectus Division, 200 West Road, New York, NY 10282, by facsimile at 212-902-9316, by electronic mail at [email protected] mail.gs.com, or by calling 1-866-471-2526.; or Piper Sandler, by electronic mail at [email protected], or by calling (800) 747-3924.

A registration assertion relating to those securities has been filed with the U.S. Securities and Change Fee and was declared efficient on March 5, 2025. This press release shall not represent an offer to promote or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction by which such offer, solicitation or sale could be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.

About Kestra

Kestra Medical Applied sciences, Ltd. is a commercial-stage wearable medical system and digital healthcare company centered on reworking affected person outcomes in heart problems utilizing monitoring and therapeutic intervention applied sciences which might be intuitive, clever, and related.

Disclaimer

“Wolfe | Nomura Alliance” is the advertising identify utilized by Wolfe Analysis Securities and Nomura Securities Worldwide, Inc. in reference to sure equity capital markets actions performed collectively by the companies. Each Nomura and Wolfe Analysis Securities are serving as underwriters within the offering described herein. As well as, Wolfe Analysis Securities could present gross sales help providers, investor suggestions, investor training, and/or different impartial equity analysis providers in reference to the offering.

Investor Contact

Marissa Bych or Webb Campbell

Gilmartin Group

[email protected]

This text was initially printed on Quiver Information, learn the total story.

The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.